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ABSTRACT
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that
accounts for about 60 to 80% of dementia cases worldwide. AD is characterized by two
important physiological features: extracellular senile plaques consisting of β-amyloid
(Aβ) peptide that is cleaved from a larger protein called the amyloid precursor protein
(APP), and intracellular neurofibrillary tangles (NFTs) containing hyperphosphorylated
tau protein. The pathogenesis of sporadic or late-onset AD (LOAD) which represents
95% of the cases appears to not be heritable and may be related to epigenetic
programming and environmental factors acquired earlier in life. Apolipoprotein allele
4 (ApoE4) protein is encoded by the ApoE gene and is considered the only established
genetic risk factor for LOAD. It is suggested that ApoE4 affects the pathogenesis of AD
by increasing tau hyperphosphorylation, inhibiting the clearance of amyloid-β (Aβ), and
promoting Aβ aggregation. Perfluorooctanesulfonic acid (PFOS) is a persistent organic
pollutant known to cause neurotoxicity and poses a major threat to the ecosystem and
human health. The aim of this study was to investigate PFOS as a potential risk factor
for LOAD by assessing the potential mechanism and impact of PFOS on three major
AD-associated pathways: amyloidogenesis, tau pathology, and ApoE using in vivo and
in vitro models. Our findings demonstrated that SH-SY5Y neuroblastoma cells exposed
to low concentrations of PFOS showed increased protein levels of APP, tau, and
phosphorylated tau (p-tau) at Ser-404 and Thr-181 sites. PFOS exposure also caused an
elevation in the kinase GSK3β, ApoE4 protein levels in vitro; however, only GSK3β
and ApoE were modulated in vivo. These data suggest that ApoE4 is inducible by

environmental exposure to PFOS and may play a role in AD pathogenesis primarily by
modulating the tau pathway via a mechanism that involves GSK3β.
Keywords: PFOS, ApoE4, Late-onset Alzheimer’s disease, amyloidogenic pathway,
Tau pathology, glycogen synthase kinase-3 beta (GSK3β).
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PREFACE
This thesis was written in a manuscript format according to the University of
Rhode Island Graduate School guidelines and consists of one manuscript that satisfy the
requirements of the Department of Biomedical and Pharmaceutical Sciences, College
of Pharmacy, University of Rhode Island.
MANUSCRIPT: Perfluorooctanesulfonic acid (PFOS) as a potential risk factor
for late-onset Alzheimer’s disease. This manuscript has been prepared for submission
to “Toxicology and Applied Pharmacology”.
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INTRODUCTION
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that
accounts for about 60 to 80% of dementia cases worldwide1,2. Several pathologies have
been implicated with AD including neuroinflammation, microglia activation, and oxidative
stress3. The major AD hallmarks are the presence of extracellular senile plaque consisting
of β-amyloid (Aβ) peptide that is cleaved from a larger protein called the amyloid precursor
protein

(APP),

and

intracellular

neurofibrillary

tangles

(NFTs)

containing

hyperphosphorylated tau protein4. Tau is the major neuronal intracellular microtubule
binding protein, it is essential for stabilization of microtubules, and axonal transport in
neurons5. Hyperphosphorylated tau which occurs in pathological conditions, reduces tau
affinity to microtubules and impairs axonal transport6,7. Several protein kinases are
involved in the phosphorylation of tau protein such as the proline-directed protein kinases:
cyclin-dependent kinase-5 (CDK5) and glycogen synthase kinase-3 beta (GSK3β)8.
The etiology of Late-onset Alzheimer’s Disease (LOAD) which represents 95% of
the cases is sporadic in nature and the only established gene associated with LOAD is
Apolipoprotein (ApoE)9. Mounting evidence has indicated that the human ApoE gene is
the strongest genetic risk factor for the development of LOAD10,11. The presence of one
copy of ApoE4 allele increases the risk of acquiring LOAD by about 3 times while the
risk is increased by 15-fold if 2 copies of ApoE4 allele are present9,11. In the central nervous
system (CNS), ApoE is involved with the repair process after injury10, it functions as a
lipid transporter and/ or signaling molecule12,13. There are 3 different isoforms of ApoE in
humans, however, ApoE4 is the one mainly associated with increased prevalence of
AD9,10,14. Previous studies have reported that fragments of ApoE4 accumulated in NFTs in
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brains of AD patients15, and are detected in neurons of ApoE4 transgenic mice16. ApoE4
appears to result in behavioral deficits and neurodegeneration through disruption of the
cytoskeleton, stimulation of tau phosphorylation, generation of NFTs17,16,18 as well as by
interfering in Aβ clearance thereby facilitating the aggregation of Aβ and formation of
senile plaque9,10,11,17,19,20,21.
The random nature of LOAD suggests that environmental factors may contribute
to the onset of LOAD, particularly environmental exposures acquired earlier in life22. Polyand perfluoroalkyl substances (PFASs) are a class of emerging persistent organic pollutants
(POPs) with neurotoxic properties. They are manmade fluorinated chemicals that have
been widely used in numerous industrial and consumer products such as textile products,
firefighting foams, and oil-resistant coatings for paper products. PFASs persist in the
environment and bioaccumulate in the food chain 23. One of the most widely used PFASs
is the 8-carbon chain (C8) Perfluorooctanesulfonic acid (PFOS) which has been detected
in adult human serum24 and in children with a serum concentration equal or even higher
than adults25. PFOS can cross the placenta, the blood brain barrier (BBB) 26,27,28and was
found in breast milk

29

. PFOS strongly binds to plasma albumin30 and it has an average

serum half-life of 5.4 years in humans 31, and 36.9 days for CD-1 mice32.
Even though levels of PFOS exposure have decreased during the last decade due to
industrial pashing out of PFOS, it persists in the environment due to its resistance to
photolysis, hydrolysis, and biodegradation23. Developmental studies using rodents showed
that exposure to PFOS can cause neural damage manifested by chronic glial activation,
release of inflammatory factors33, altered susceptibility of the cholinergic system, resulting
in behavioral deficits, reduced spatial learning, memory and cognitive impairment which
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can persist into adulthood

34,35,36,37

. Neonatal exposure of mice to a single PFOS dose

21𝜇mol/kg body weight (11.3 mg/kg body weight) on PND 10 increased cerebral tau
protein expression and caused behavioral abnormalities in adult mice

34, 37,38

. Moreover,

PFOS resulted in an increase in β-amyloid aggregation, increased tau levels, and tau
hyperphosphorylation in adult rats39 suggesting an association between developmental
PFOS exposure and LOAD.
Therefore, the main aim of this study was to investigate the potential of PFOS
exposure as a risk factor for LOAD by assessing its impact on biomarkers associated with
three major AD-related pathways in an in vitro model using the human SH-SY5Y
neuroblastoma cell line. Furthermore, the same pathways were examined following
developmental PFOS exposure in timed-pregnant CD-1mice.
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MATERIALS AND METHODS
Animal model and PFOS exposure
Twelve timed-pregnant CD-1 mice were purchased from Charles River
Laboratories (Wilmington, MA). The pregnant dams were received on gestation day 1
(GD)1 at the University of Rhode Island (URI) Comparative Biology Resource Center
(CBRC). Upon arrival, the dams were weighed and housed individually in a designated
room with controlled temperature (20-26°C), relative humidity (30-70%), and 12:12 hour
light-dark cycle (light on at 6:00 AM; light off at 6:00 pm) where standard chow diet (SD;
Teklad Extruded global diet, 2020X) and water were provided ad-libitum. Dams were
randomly assigned into two treatment groups (n= 6 per treatment group) and were dosed
with either vehicle ( 0.5% Tween-20 in deionized water) or 1 mg/kg/day PFOS (396575,
Sigma Aldrich, St. Louis, MO) dissolved in deionized water with 0.5% Tween-20 via oral
gavage throughout gestation (GD1-GD18 or 19 [birth]) and lactation (birth to postnatal day
[PND] 20) as shown in figure 1.
For dose calculation, the dams body weights were recorded every 3-4 days and the
last dose given was on PND 19. On PND 1, neonates were randomly assigned to dams
within the same treatment group with 10 pups assigned to each dam in order to ensure equal
lactational PFOS exposure, excess pups were culled. On PND 20, dams and pups were
fasted for 4-6 hours and euthanized via cardiac puncture with subsequent decapitation. The
brain tissues were collected and stored at -80°C for biomarker assessment. During this
study, the animals were under the supervision of the URI CBRC staff. The animal protocols
and the study procedures were reviewed and approved by the University of Rhode Island
Institutional (URI) Animal Care and Use Committee (IACUC).
5

Cell culture
Human neuroblastoma SH-SY5Y cells were purchased from American Type
Culture Collection (ATCC, Manassas, VA). Cells were cultured in Dulbecco’s Modified
Eagle Medium (DMEM)/F12 (Invitrogen, MD) supplemented with 10% fetal bovine serum
(FBS) (Thermo Scientific, Waltham, MA), 100 U/ml penicillin, 100 μg/ml streptomycin,
and 2 mM L-glutamine (Sigma Aldrich, St. Louis, MO) in T-75 tissue culture flasks with
vented lids (Cyto-one, USA Scientific) in a CO2 incubator maintained at 5% CO2 and 37°C.
Cells were then sub-cultured at a density of 105 cells/mL into a six-well plate and upon
80% confluency, cells were differentiated for 6 days using 10 µM all-trans retinoic acid
(Sigma Aldrich, St. Louis, MO) dissolved in DMEM/F12 medium containing 1% FBS, 100
U/ml penicillin, 100 μg/ml streptomycin in the dark. Cells were observed for neurite outgrowth with media being changed every 48 hours as described previously40. Furthermore,
differentiated cells were exposed to PFOS dissolved in DMSO for 24, 48, and 72 hours at
37°C with the following concentrations: 0, 0.001, 0.1, 5, 25, 50, 100 µM. The concentration
of DMSO in the cell culture media was maintained at 0.1% for control and across all
treatment groups.

MTS assay
The viability of differentiated SH-SY5Y human neuroblastoma cells was assessed
after exposure to PFOS using the MTS assay kit (Promega, Madison, WI). The cells were
seeded in 96-well plate (2 x 10 4cells/well) and treated with different concentrations of
PFOS ranging from 0-100 µM for 24, 48, and 72 hours. After the completion of the
incubation period, the media containing PFOS was aspirated out and fresh media with no
PFOS was added in each well followed by treatment with 20 µl of MTS solution. The plates
6

were incubated at 37°C for 2 hours and after incubation, the absorbance was measured at
490nm by using the Spectramax M2 Multi-mode microplate reader (Molecular Devices,
San Jose, CA).

Protein Extraction and Western Blotting
The brain cortex samples and cells were lysed using radio-immunoprecipitation
assay (RIPA) lysis buffer (Sigma Aldrich, MO) supplemented with phosphatase and
protease inhibitor tablet: one tablet was dissolved in 10 ml of RIPA buffer (Pierce Protease
and Phosphatase Inhibitor Mini Tablets, EDTA-Free, Thermo Scientific, Waltham, MA).
The samples were incubated on ice for 30 min, then vortexed and sonicated for 5 minutes.
The samples were subsequently centrifuged at 10,000 g for 20 min and the supernatants
were collected and stored at -80C for protein quantification and western blot analysis. The
protein concentration was determined using Micro BCA protein assay kit (Thermo
Scientific, Waltham, MA). For western, at least 20 µg of total protein was first separated
by sodium dodecyl sulfate polyacrylamide gels (SDS-Page) on 4-15% Mini-protean®
TGXTM precast gels (Bio-Rad, Hercules, CA), and then transferred to polyvinylidene
fluoride (PVDF) membranes (GE-Healthcare, Piscataway, NJ). The membranes were
blocked for 1 hour at room temperature with gentle agitation in blocking buffer comprising
5% (w/v) bovine serum albumin (BSA) in Tris-Buffered saline with 0.1% Tween-20
(TBST, pH 7.4).
Immunoblotting was then performed by incubating the membranes with gentle
agitation on a shaker overnight at 4C with primary antibodies of interest: Rabbit AntiApoE (Thermo Scientific, Waltham, MA), Mouse Anti-ApoE4, Mouse Anti-Tau-46,
Rabbit Anti-Ser404, Rabbit Anti-Thr181, Rabbit Anti-GSK3β, Rabbit Anti-CDK5, Rabbit
7

Anti-APP (Cell Signaling Technology, MA) at a dilution of 1:1000 in TBST. On the
following day, the membranes were washed three times with TBST for 5 min each and
exposed at room temperature for 1 hour to either goat anti-mouse or goat anti-rabbit
IRDye® 680 or 800 LT infrared dye (LI-COR Biotechnology, Lincoln, NE) at a 1: 10,000
dilution factor in TBST then the membranes were again washed three times with TBST.
Also, the specific target protein/GAPDH ratio was obtained by re-probing the membranes
for 2 hours at room temperature with primary antibody for the protein Glyceraldehyde 3phosphate dehydrogenase (Rabbit Anti-GAPDH) at 1:5,000 dilution as a control, followed
by washing and re-exposure to goat anti-rabbit IRDye® 680 or 800 LT infrared dye (LICOR Biotechnology, Lincoln, NE) at a 1: 10,000 dilution factor in TBST (Cell Signaling
Technology, MA). Finally, images were captured using the Odyssey® Infrared Imaging
System (Li-Cor, NE), and Band intensities were measured using NIH ImageJ software and
normalized against GAPDH.

Total RNA isolation, synthesis of cDNA, and RT-q PCR
Total RNA was isolated from cerebral cortex tissues and the SH-SY5Y cells using
the TRIzol reagent method (Invitrogen, Carlsbad, CA). The integrity of the isolated RNA
was verified by NanoDrop (Thermo Scientific, Wilmington, DE) analysis. The
complementary DNA (cDNA) was then synthesized following the manufacturer’s
instruction by using the iScriptTM Select cDNA synthesis kit (Bio-Rad, Hercules, CA). The
reaction mixture consisted of 1µg of RNA diluted in 4 µl 5X iScript reaction mix, 1 µl
iScript reverse transcriptase in a total volume of 20 µl of RNA free water. Using MJ
Research MiniCycleTM (Bio-Rad, Hercules, CA) the samples were incubated for 26
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minutes using the following protocol, Priming for 5 min at 25C, reverse transcription at
46 C for 20 min, RT inactivation 1 min at 95 C.
Primer pairs for mouse tau, APP, GSK3β, CDK5, GAPDH and human tau, APP,
GSK3β, CDK5 and GAPDH were obtained from integrated DNA Technologies IDT
(Coralville, IA, USA) as follows: mouse tau F: 5’-CCTGAGCAAAGTGACCTCCAAG3’; and tau R: 5’-CAAGGAGCCAATCTTCGACTGG-3’; mouse APP F: 5’-TGCAGC
AGAACGGATATGAG-3’; and APP R: 5’-ACACCGATGGGTAGTGAAGC-3’; mouse
GSK3β F: 5’-AGGAAGGAAAAGGTGATTCAAGA-3’; and GSK3β R: 5’-TGCTGCCA
TCTTTATCTCTGCT-3’; mouse CDK5 F: 5’-GGGACCTGTTGCAGAACCTAT-3’; and
CDK5 R: 5’-AGTCAGAGAAGTAGGGGTGCT-3’; mouse GAPDH F: 5’-TGGTGA
AGCAGGCATCTGAG-3’; and GAPDH R: 5’-TGCTGTTGAAGTCGCAGGAG-3;
human tau F: 5’-TGAACCAGGATGGCTGAGC-3’, and tau R: 5’-TTGTCATCGCTTC
CAGTCC-3’; human APP F: 5’-CTGTGGCAGACTGAACATGC-3’, and APP R: 5’TGTTCAGAGCACACCTCTCG-3’; human GSK3β F: 5’- GGATTCGTCAGGAACAG
GACA-3’, and GSK3β R: 5’-AGTATTAGCATCTGACGCTGC-3’; human CDK5 F: 5’GATGATGAGGGTGTGCCGAG-3’, and CDK5 R: 5’-TGCGGCTATGACAGAATCC
C-3’; human GAPDH F: 5’-AGGTCGGAGTCAACGGATTT-3’, and GAPDH R: 5’TTCCCGTTCTCAGCCTTGAC-3’. Real-time PCR was carried out in 20 µl reaction
volumes containing 1 µl of each forward and reverse primers, 1 µl of cDNA, 7 µl of
nuclease-free water, and 10 µl of SYBR® Green PCR Master Mix (Applied Biosystems,
Foster City, CA). The qPCR reaction was performed following the standard protocol:
samples were incubated for 2 min at 50°C, then for 10 min at 95°C, followed by 15 seconds
at 95°C for 40 cycles and for 1 min at 60°C By using the ViiA7 real-time PCR system
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(Applied Biosystems, Foster City, CA). GAPDH mRNA expression was used as the
endogenous control and the data was reported using the 2-ΔΔCT method.

Enzyme Linked Immunosorbent Assay (ELISA)
Cortex tissues were weighed and homogenized in eight volumes of an ice-cold
solution containing 5 M guanidine HCl dissolved in 50 mM Tris-HCl, PH 8.0 (Sigma
Aldrich, St. Louis, MO). The mixture was maintained for 3-4 hours at room temperature
and then diluted with ice-cold Phosphate buffer saline (PBS) supplemented with 1X
protease and phosphatase inhibitor (Thermo Scientific, Waltham, MA) until reaching a
final concentration of 0.1 M guanidine. The samples were centrifuged for 20 minutes at
16,000 g at 4°C and the resulting supernatant was maintained either on ice for Aβ
quantification or stored at -80°C for later use. ELISA kit catalog numbers KMB3441 and
KMB3481 (Thermo Scientific, Waltham, MA) were used according to the manufacturer’s
instruction for quantification of Aβ1-42 and Aβ1-40 respectively.
These ELISA kits contain a colorimetric detection with double ELISA antibody
approach. In each kit, the N-terminus of the mouse Aβ is determined by the monoclonal
antibody coated in the wells. The Standards (provided in the kit) and the samples containing
the Aβ antigen were added to the wells with the appropriate dilution (100 µl in each well).
The plates were maintained at room temperature for 2 hours to allow the binding of the
immobilized (capture) antibody and the Aβ antigen. Then, the plates were washed four
times by using the washing solution provided in the kit. Subsequently, a solution of rabbit
antibody specific for the C-terminus of either Aβ1-42 or Aβ1-40 was added to the wells (100
µl in each well) except for the blanks. The plates were then covered and incubated again
for 1 hour at room temperature. After incubation, the wells were washed 4X using the
10

washing solution and 100 µl of horseradish-peroxidase-labeled anti-rabbit antibody was
added to each well except for the blanks. Then, the plate was covered and incubated at
room temperature for 30 minutes followed by four times washing. Then, 100 µl of the
stabilized chromogen solution was added to each well and the plate was incubated at room
temperature for 20-30 minutes in the dark. Once, the reaction mixtures turned blue, 100 µl
per well of the stop solution was added to each well to stop the reaction and the mixture
turned yellow. Finally, the absorbance was detected at 450 nm using the Spectramax M2
Multi-mode microplate reader (Molecular Devices, San Jose, CA)

Statistical analysis
The results of various exposed groups versus the control were expressed as the
mean ± the standard error of the mean (SEM). The data were analyzed by using the
statistical tests: unpaired two-tailed Student's t-test for comparison between two groups and
the one-way analysis of variance (ANOVA) followed by the Dunnett or Tukey test for
multigroup comparisons. The GraphPad Prism 8.0 computer software (La Jolla, CA, USA)
was used for the analysis, and p-value < 0.05 was considered to indicate a statistically
significant difference.
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RESULTS
Effects of PFOS exposure on SH-SY5Y cell viability
Differentiated SH-SY5Y cells were exposed to a series of PFOS concentrations (0,
0.001, 0.1, 1, 5, 25, 50, 100 µM) and cell viability was determined using the MTS assay
following 24, 48, and 72 h of exposure. At 24h, There was no significant cytotoxicity
observed. However, at 48 (100 µM) and at 72 h (25, 50, 100 µM) concentrations of PFOS
revealed significant decreases in cell viability (p= 0.05, p< 0.001). Thus, PFOS exposure
at concentrations (0.001, 0.1 µM) for 24 h were considered appropriate for further studies
(Figure 2).
PFOS effects on APP mRNA and protein levels in differentiated SH-SY5Y cells.
(amyloidogenic pathway)
Further, we investigated the effects of PFOS on AD biomarkers related to the
amyloidogenic pathway in human neuroblastoma SH-SY5Y cells. APP protein level was
significantly elevated as compared to the control after 24 h exposure to 0.001 µM
concentration of PFOS, p= 0.0152 (Figure 3A, B). We did not observe any effects on APP
mRNA levels (Figure 3C).
PFOS effects on Tau mRNA expression, Total Tau, and P-tau protein levels in
differentiated SH-SY5Y cells (tau Pathway)
SH-SY5Y cells showed a significant increase in total tau, P-tau (Ser-404) and Ptau (Thr-181) protein levels as compared to controls after 24 h exposure to 0.001 µM of
PFOS, P= 0.0307, P= 0.0062, P=0.036 respectively (Figure 4A, B, D-G). Also, P-tau (Ser404) was significantly elevated as compared to controls in SH-SY5Y cells after 24 h
exposure to 0.1 µM of PFOS, P= 0.0058 (Figure 4D, E). Based on one-way ANOVA, there

12

was no effect of PFOS exposure on total tau mRNA expression (Figure 4C). Next, we
investigated the effect of PFOS on kinase pathways in differentiated SH-SY5Y cells.
GSK3β protein levels were significantly increased as compared to controls following 24 h
exposure of SH-SY5Y cells to PFOS at 0.001 µM concentration, p=0.012 analyzed by the
one-way ANOVA (Figure 5A, B). We did not observe any significant changes in CDK5
protein levels and mRNA expression levels of GSK3β and CDK5 (Figure 5C-F), based on
a one-way ANOVA followed by Dunnett’s for multiple comparisons.
PFOS effects on ApoE and ApoE4 protein levels in differentiated SH-SY5Y cells
(Non-neural Pathway)
We further analyzed the impact of PFOS exposure on non-neural pathways
associated with AD. SH-SY5Y cells exposed to PFOS at 0.001 µM concentration for 24 h,
showed a significant increase in ApoE4 protein levels as compared to controls, P= 0.026
(Figure 6C, D) analyzed by the one-way ANOVA followed by Dunnett’s for multiple
comparisons. Interestingly, PFOS had no effect on total ApoE protein levels in SH-SY5Y
exposed cells at 0.001 and 0.1 µM concentrations following 24 h of exposure (Figure 6A,
B).
Effects of developmental exposure of PFOS on APP mRNA expression, APP protein
levels, Aβ1-42 and Aβ1-40 accumulation (amyloidogenic pathway)
We observed an increasing trend in the effect of PFOS exposure on APP mRNA
expression and APP protein levels as compared to controls (Figure 7A-C). PFOS exposure
caused an increased trend in Aβ42 and the ratio of Aβ42/Aβ40 proteins levels, however, these
findings were not statistically significant. The Aβ40 protein levels were not affected (Figure
7D-F).
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Effects of developmental PFOS exposure on Tau mRNA expression, Total Tau and
P-tau protein levels (tau Pathway)
Tau mRNA expression in the cortex of PFOS exposed group showed no significant
difference as compared to controls (Figure 8C). Western blot analysis showed no
significant difference between the PFOS exposed group and the control group in Total tau
and P-tau (Ser-404) protein levels (Figure 8A, B, D, E). The protein level of P-tau (Thr181) was trending higher in the PFOS exposed group compared to controls (Figure 8F, G).
The PFOS exposed group showed a significant increase in GSK3β protein levels as
compared to control group, p= 0.05 determined by two-tailed unpaired t-test (Figure 9A,
B). The GSK3β mRNA expression was trending higher in the PFOS exposed group
compared to controls (Figure 9C). We did not observe any significant effects on CDK5
mRNA expression and protein levels in the PFOS treated group compared with the control
group (Figure 9D-F).
Effects of developmental PFOS exposure on ApoE protein levels (Non-neural
Pathway)
Western blot analysis showed that PFOS significantly increased total ApoE protein
levels in brain cortex as compared to the control group, p= 0.0025 analyzed by two-tailed
unpaired t-test (Figure 10A, B).
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DISCUSSION

As a persistent organic pollutant, PFOS has been identified as a developmental
neurotoxicant24,41,42. Previous studies have reported the developmental effects of PFOS on
neurological disorders, behavioral disorders, and cognitive function35,43,44. A few reports
indicated that developmental exposure to PFOS induced tau protein levels37 and enhanced
AD pathological hallmarks45. However, the effects of PFOS on amyloidogenic, tau, kinase,
and non-neural pathways related to AD are not fully elucidated in the literature.
Previous work from our lab has demonstrated that developmental exposure to
environmental toxins such as lead (Pb) induced cognitive deficits, latent overexpression of
tau, and phosphorylated tau in the adult rodents cortex46,47. In addition, differentiated
human neuroblastoma cells (SH-SY5Y) exposed to a series of Pb concentrations (0-100
µM) for 48 h showed an alteration in tau and hyperphosphorylation of tau48. Therefore, we
performed in vivo and in vitro studies to investigate potential PFOS impacts on AD related
biomarkers and pathways.
The present study established that the concentrations range of PFOS (0-100 µM)
had no significant cytotoxicity on differentiated SH-SY5Y cells following 24 h of exposure
(Figure 2), and revealed that PFOS may impact the amyloidogenic pathway which was
indicated by elevation of amyloid precursor protein (APP) levels (Figure 3A, B) at 0.001
µM of PFOS in SH-SY5Y cells. Furthermore, overexpression of tau and site-specific
hyperphosphorylation of tau (Ser-404 and Thr181) proteins were both induced by PFOS in
SHSY5Y cells at very low concentrations (0.001and 0.1 µM) (Figure 4A, B, D-G)
providing more evidence that PFOS can promote AD pathogenesis through modulating the
tau pathway. The upregulation of total tau and the abnormal hyperphosphorylation of tau
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(P-tau) proteins are responsible for the loss of microtubule stability and axonal transport in
AD49,50. This is consistent with the study by Zhang et al (2016) which reported that
developmental exposure to PFOS induced β-amyloid aggregation, total tau, and
phosphorylated tau proteins levels in adult rats at PND 9045. Also, Johansson et al (2009)
reported that neonatal mice exposed to a single PFOS dose on PND 10 showed a significant
elevation of cerebral tau protein levels37. This is consistent with our data suggesting the
impact of PFOS on amyloidogenic and tau pathways related to AD.
Moreover, we investigated the effect of PFOS on the kinase pathways that are
associated with AD. GSK3β is an active serine/threonine proline-directed kinase, it is
involved in many processes including inflammatory responses, memory impairment,
cholinergic deficits, increased the production of Aβ and hyperphosphorylation of tau51.
Also, the sites of tau phosphorylation found in AD brain are proline-directed (Thr-Pro or
Ser-Pro). Thus, GSK3β plays an important role in the pathogenesis of AD52. In this study,
we observed the ability of PFOS to promote an increase in the GSK3β protein levels at
very low concentrations (0.001 µM; Figure 5A, B). There was no effect observed on CDK5
(Figure 5D-F).
In addition to the most common neural pathways associated with AD, this study to
our knowledge is the first study to investigate the effect of PFOS on non-neural pathways
associated with AD, namely Apolipoprotein E (ApoE). It has been reported that ApoE4
can stimulate the phosphorylation of tau and the generation of NFTs18 as well as facilitating
the aggregation of Aβ and formation of senile plaque9,10,11,17. Also, a recent in vitro study
indicated that GSK3β activity can be upregulated by ApoE4 through the inhibition of the
wnt signaling pathway via Low-density lipoprotein-related protein-5 and -6 (LRP5 and
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LRP6) receptors53. The invitro work here showed that PFOS exposure at 0.001 µM for 24
h increased ApoE4 protein levels significantly (Figure 6C, D). It is worth noting here that
our in vivo findings did not demonstrate that PFOS exposure alters amyloidogenic and tau
pathways in wild-type CD-1 mice on PND 20 (Figure 7 and 8). Similar to previous
developmental behavioral study by Butenhoff et al 2009 indicated that rat offspring
exposed from GD0 to PND 20 to 1 mg/kg/day PFOS didn’t show any changes in learning
and memory abilities on PND 2054. However, this is in contrast with what was previously
published by Zhang et al 2016 and Johansson et al 2009. Thereby, It should be pointed out
that in our study PFOS was given to dams via oral gavage and we focused on perinatal
exposure of pups to PFOS during gestation and lactation till PND 20, the study by Zhang
et al 2016 the dams were given PFOS in drinking water and they studied both perinatal
exposure of pups and direct exposure till PND 90. Therefore, the complex physiological
activities during the brain developmental stages including the brain growth spurt (BGS)
and the establishment of the BBB, as well as the experimental design, time points, animal
model, and the duration of exposure might explain the differences in the findings.
Furthermore, our in vivo data showed that developmental exposure to PFOS caused
a significant increase in GSK3β protein levels (Figure 9A, B). PFOS resulted in a
significant elevation of ApoE protein levels in the cerebral cortex of wild-type CD-1 mice
(Figure 10A, B). It is noteworthy here that humans express 3 isoforms of ApoE (h-ApoE)
protein while mice express only one isoform (m-ApoE)55. The homology of the amino acid
sequences between the h-ApoE and the m-ApoE is only 70%. Although m-ApoE contains
the equivalent Arg112/Arg158 residues present in h-ApoE4, several studies have indicated
differences between them including that h-ApoE functions as two distinct protein domains
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while m-ApoE functions as a single domain protein56. However, it has been demonstrated
that the m-ApoE is involved in Aβ amyloid deposition in APP transgenic (Tg) mice that
develop Aβ aggregation57,58.
Although our in vivo and in vitro findings indicated changes in the protein levels of key
biomarkers related to major AD associated pathways, PFOS caused no changes in the
mRNA expression of these biomarkers in disagreement with Zhang el at 2016 and
others35,59,60 possibly due to differences in the study design as mentioned above. It is also
worth noting that effects of PFOS exposure were mainly in the lower concentrations range
and for a short duration (24 hours), consistent with previous studies on other cell types that
described the dose-response curve of PFOS as a bell-shaped and non-monotonic35,61. Liao
et al (2008) reported that 1 µM of PFOS resulted in an increase of glutamate-activated
current while 100 µM showed a suppressive effect in cultured primary hippocampal
neurons62. Additionally, it was indicated that the effects of PFOS exposure on other cell
types such as HAPI microglial cells and glioma cells generally reach a peak in short periods
and then decline suggesting that the cultured cells may develop tolerability to PFOS by
some mechanisms63,64. It is worth noting here that this study has limitations. Transgenic
mice with human APP, Tau, and expressing human ApoE isoforms would further elucidate
the mechanism by which PFOS exposure induces AD pathogenesis. Additionally, studying
the effect of PFOS exposure on other CNS cells such as microglia and astrocytes can
further recapitulate the impact of PFOS on ApoE and to understand the mechanism of
PFOS inducing neurodegeneration.
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CONCLUSION
The results presented herein suggest that PFOS impacts amyloidogenic, tau, and
kinase pathways related to AD particularly in human cells through the upregulation of
ApoE4 protein levels via a mechanism associated with GSK3β. This study may contribute
to understanding the mechanism by which PFOS triggers AD pathogenesis. However,
further investigation is warranted such as examination of potential involvement of
phosphatase enzymes, microRNA, cellular degradation pathways including insulin
degrading enzymes in the mechanism of PFOS to further confirm these findings and to
provide an insight into the neurodegenerative mechanisms induced by PFOS.
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Figure 1. Scheme of PFOS exposure in timed-pregnant CD-1 mice. Pregnant mice were
given either 1 mg/kg/day PFOS in water with 0.5% Tween-20 or vehicle (0.5% Tween-20
in water) via oral gavage throughout gestation (GD1-GD18 or 19 [birth]) and lactation
(birth to postnatal day [PND] 20). Brain tissues were collected from pups at PND 20 (n=4
per treatment group).
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Figure 2. Effects of PFOS exposure on SH-SY5Y cells viability. Cells were exposed to
a series of PFOS concentrations (0, 0.001, 0.1, 1, 5, 25, 50, 100 µM) for 24, 48 and 72 h
followed by MTS assay. Data are expressed as mean ± S.E.M using the one-way ANOVA
followed by Dunnett’s for multiple comparisons, n=4 (*P< 0.05, **P< 0.01, ***P< 0.001).
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Figure 3. APP mRNA and protein levels in differentiated SH-SY5Y cells after PFOS
exposure (amyloidogenic pathway). Differentiated SH-SY5Y cells exposed to PFOS at
0.001 and 0.1 µM concentrations for 24 h. (A-B) quantification of APP protein levels
normalized to GAPDH. (C) APP mRNA levels. Results are expressed as mean ± S.E.M
using the one-way ANOVA followed by Dunnett’s for multiple comparisons, n=3 (*P<
0.05, **P< 0.01).
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Figure 4. Tau mRNA and protein levels in differentiated SH-SY5Y cells after PFOS
exposure (tau pathway). Differentiated SH-SY5Y cells exposed to PFOS at 0.001 and 0.1
µM concentrations for 24 h. (A-B) quantification of Tau protein levels normalized to
GAPDH. (C) Tau mRNA levels. (D-E) quantification of p-tau (ser404) protein levels
normalized to GAPDH. (F-G) quantification of p-tau (Thr 181) protein levels normalized
to GAPDH. Results are expressed as mean ± S.E.M using the one-way ANOVA followed
by Dunnett’s for multiple comparisons n=3 (*P< 0.05, **P< 0.01).
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Figure 5. GSK3β, CDK5 mRNA, and protein levels in differentiated SH-SY5Y cells
after PFOS exposure (kinase pathway). Differentiated SH-SY5Y cells exposed to PFOS
at 0.001 and 0.1 µM concentrations for 24 h. (A-B) quantification of GSK3β protein levels
normalized to GAPDH. (C) GSK3β mRNA levels. (D-E) quantification of CDK5 protein
levels normalized to GAPDH. (F) CDK5 mRNA levels. Results are expressed as mean ±
S.E.M using the one-way ANOVA followed by Dunnett’s for multiple comparisons, n=3
(*P< 0.05, **P< 0.01).
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Figure 6. ApoE protein levels in differentiated SH-SY5Y cells after PFOS exposure
(non-neural pathway). Differentiated SH-SY5Y cells exposed to PFOS at 0.001 and 0.1
µM concentrations for 24 h. (A-B) quantification of ApoE protein levels normalized to
GAPDH. (C-D) quantification of ApoE4 protein levels normalized to GAPDH. Results are
expressed as mean ± S.E.M using the one-way ANOVA followed by Dunnett’s for multiple
comparisons, n=3 (*P< 0.05, **P< 0.01).
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Figure 7. APP mRNA and protein levels at PND 20 in the cortex of CD-1 pup mice
developmentally exposed to PFOS (amyloidogenic pathway). Timed-pregnant female
CD-1 mice were administered with vehicle (0.5% Tween-20 in water) or 1 mg/kg/day
PFOS in water with 0.5% Tween-20 via oral gavage from gestation GD1 through postnatal
day PND 20. (A-B) quantification of APP protein levels normalized to GAPDH. (C) APP
mRNA levels. (D-E) quantification of Aβ 1-42 and Aβ 1-40 protein levels normalized to
GAPDH. (F) Aβ 1-42: Aβ 1-40 ratio. Results are expressed as mean ± S.E.M using the
two-tailed unpaired t-test, n=4. Results were non-significant.
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Figure 8. Tau mRNA and protein levels at PND 20 in the cortex of CD-1 pup mice
developmentally exposed to PFOS (tau pathway). Timed-pregnant female CD-1 mice
were administered with vehicle (0.5% Tween-20 in water) or 1 mg/kg/day PFOS in water
with 0.5% Tween-20 via oral gavage from gestation GD1 through postnatal day PND 20.
(A-B) quantification of Tau protein levels normalized to GAPDH. (C) Tau mRNA levels.
(D-E) quantification of p-tau (ser404) protein levels normalized to GAPDH. (F-G)
quantification of p-tau (Thr 181) protein levels normalized to GAPDH. Results are
expressed as mean ± S.E.M using the two-tailed unpaired t-test, n=4. Results don’t indicate
a significant difference between the two groups.
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Figure 9. GSK3β, CDK5 mRNA levels and protein levels at PND 20 in the cortex of
CD-1 pup mice developmentally exposed to PFOS (kinase pathway). Timed-pregnant
female CD-1 mice were administered with vehicle (0.5% Tween-20 in water) or 1
mg/kg/day PFOS in water with 0.5% Tween-20 via oral gavage from gestation GD1
through postnatal day PND 20. (A-B) quantification of GSK3β protein levels normalized
to GAPDH. (C) GSK3β mRNA levels. (D-E) quantification of CDK5 protein levels
normalized to GAPDH. (F) CDK5 mRNA levels. Results are expressed as mean ± S.E.M
using the two-tailed unpaired t-test, n=4 (*P< 0.05, **P< 0.01).
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Figure 10. ApoE protein levels at PND 20 in the cortex of CD-1 pup mice
developmentally exposed to PFOS (non-neural pathway). Timed-pregnant female CD1 mice were administered with vehicle (0.5% Tween-20 in water) or 1 mg/kg/day PFOS in
water with 0.5% Tween-20 via oral gavage from gestation GD1 through postnatal day PND
20. (A-B) quantification of ApoE protein levels normalized to GAPDH. Results are
expressed as mean ± S.E.M using the two-tailed unpaired t-test, n=4 (*P< 0.05, **P< 0.01).
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